Group 1 - The core point of the article is that Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection [1] Group 2 - The acceptance of the clinical trial application indicates a significant step forward for the company's product development in the domestic market [1] - This development may enhance the company's position in the pharmaceutical industry, particularly in the monoclonal antibody segment [1] - The news reflects the ongoing regulatory support for innovative drug development in China [1]

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received a notice of acceptance from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection, which is intended for the treatment of non-infectious uveitis [1] Group 1 - The clinical trial application for Fuxin Qibai monoclonal antibody has been accepted, indicating progress in the drug development process [1] - Fuxin Qibai is a fully human anti-IL-1β monoclonal antibody developed by Changchun Jinsai Pharmaceutical, designed to specifically block the binding of IL-1β to its receptor IL-1R [1] - Currently, there are no similar drugs approved for the same disease area in both domestic and international markets, highlighting a potential market opportunity for the company [1]

证券代码：000661 证券简称：长春高新 公告编号：2026-005 长春高新技术产业（集团）股份有限公司 关于子公司伏欣奇拜单抗注射液境内生产药品注册临床试验申请 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 获得受理的公告 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股 子公司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品 监督管理局的《受理通知书》，金赛药业伏欣奇拜单抗注射液的境内生产药品注 册临床试验申请获得受理，现将相关情况公告如下： 批的生物制剂仅有抗 TNFα类药物，且仍有相当一部分患者应答不佳或不耐受， 因此，对于安全性更好、疗效更佳以及依从性更优的新机制药物始终存在需求。 综上所述，伏欣奇拜单抗具有潜在治疗非感染性葡萄膜炎的临床价值，本次 临床试验申请受理可以推动后续该产品针对非感染性葡萄膜炎人群的临床开发。 此前，伏欣奇拜单抗注射液（水剂）已获批开展子宫内膜异位症的临床试验， 其用于急性痛风性关节炎适应症的上市申请已于 2025 年 1 月获得受理；注射用 伏欣奇拜单抗（粉剂）已获批开展用于结缔组织 ...

Core Viewpoint - The approval of Weisheng Pharmaceutical's core product, Longpei Growth Hormone Injection, marks the company's first commercialized innovative product, but it faces significant competition in the long-acting growth hormone market [3][4]. Market Overview - The Chinese growth hormone market has seen explosive growth, increasing from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, and is expected to reach 28.6 billion yuan by 2030 [3]. - The market is characterized by a shift in dosage forms, with long-acting growth hormones gaining traction due to better patient compliance compared to short-acting formulations [3][4]. Competitive Landscape - The competition in the long-acting growth hormone market is intensifying, with existing players including Changchun High-tech, Teva Biopharma, and Novo Nordisk, all of which have products already included in the national medical insurance directory [4][5]. - The entry of long-acting growth hormones into the insurance directory has led to significant price reductions, with some products seeing price drops of over 50%, thereby reducing the financial burden on patients and expanding market share [5]. Company Strategy - As a new entrant, Weisheng Pharmaceutical aims to differentiate itself by emphasizing that Longpei Growth Hormone is the only long-acting growth hormone proven to be superior to daily injections in Phase III studies, providing clear prescription guidance for doctors [6]. - The company recognizes that most growth hormone users are still self-paying, and it plans to collaborate with high-end private clinics to better reach target customers [6]. - The current penetration rate of growth hormones among children in China remains low, indicating a need for increased product awareness and education among potential users [6].

Core Viewpoint - Changchun Gaoxin (000661) emphasizes its commitment to legal compliance and risk prevention as a state-controlled listed company, ensuring healthy development through robust internal controls and integrity mechanisms [1] Group 1 - The company adheres strictly to laws and regulations as well as state-owned asset supervision requirements [1] - It has established sound internal control and integrity mechanisms to conduct its operations in accordance with the law [1] - The company adopts a zero-tolerance approach to risk prevention to ensure its healthy development [1]

证券日报网讯1月27日，长春高新（000661）在互动平台回答投资者提问时表示，公司前期所聘请的金 融与专业领域的专家，主要目的是帮助公司在全面提升公司治理能力、市场竞争力和长期可持续发展能 力等方面开展工作，但不是专门的市值管理专家。 ...

Core Insights - The competition in the long-acting growth hormone market is intensifying, with Weisheng Pharmaceutical's (02561.HK) core product, Longpei growth hormone injection, recently approved for treating children's growth hormone deficiency, marking it as the fourth long-acting growth hormone approved in China [1][2] Industry Overview - The Chinese growth hormone market has seen significant growth, expanding from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, and is projected to reach 28.6 billion yuan by 2030 [3] - The market is experiencing a shift in dosage forms, with increasing attention from parents due to "height anxiety" regarding their children's growth, leading to heightened demand for growth hormone treatments [3] Competitive Landscape - Existing competitors in the long-acting growth hormone market include Changchun High-tech (000661.SZ) with Jinsai Pharmaceutical, Teva Biologicals (688278.SH), and Novo Nordisk, with some products already included in the national medical insurance directory, resulting in significant price reductions [3] - The entry of long-acting growth hormones into the insurance directory has led to price drops of over 50%, alleviating the financial burden on patients and potentially expanding market share [3] Company Strategy - As a new market entrant, Weisheng Pharmaceutical aims to differentiate itself by promoting Longpei growth hormone as the only long-acting option proven superior to daily injections in Phase III studies, providing clear prescription guidance for doctors [4] - The majority of growth hormone users are still self-paying, and despite some long-acting products being covered by insurance, this trend is expected to continue, with a focus on partnerships with private clinics to reach target customers [4] - The current penetration rate of growth hormones among children in China remains low, indicating a need for increased product awareness and education among potential users [4]

Group 1 - The core viewpoint of the news highlights a recent pullback in the biopharmaceutical sector, with the Huatai-PineBridge Biopharmaceutical ETF (159839) declining by 2.08% while maintaining high trading volume, with nearly 600 million yuan in transactions for the day [1][4] - The ETF has seen continuous inflows, with a net subscription of over 54 million shares today and a total of over 73 million yuan in the last 10 days [1] - The ETF tracks the Guozheng Biopharmaceutical Index, which includes sectors such as CXO, vaccines, chemical drugs, blood products, and medical aesthetics, with the vaccine sector currently accounting for 15.1% of the index [6] Group 2 - A significant research breakthrough was reported by the Wuhan Institute of Virology, confirming that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this high-mortality emerging infectious disease [3] - The biopharmaceutical ETF's major component stocks mostly experienced declines, with Watson Bio and Zhi Fei Bio dropping over 6%, while Sanofi Biopharma saw an increase of over 10% [4][5] - The latest performance forecast from Sanofi Biopharma indicates an expected net profit of approximately 2.9 billion yuan for 2025, representing a year-on-year growth of 311.35% [4] Group 3 - Data from Guoxin Securities indicates a decrease in pharmaceutical holdings among funds, with the overall pharmaceutical holding ratio at 7.97%, down by 1.71 percentage points from the previous quarter [7] - The largest sub-sector in pharmaceutical holdings is chemical preparations and other biological products, while the internet pharmacy and other biological products saw the most significant decline in holdings [9] - The JPM 2026 conference highlighted the acceleration of internationalization among Chinese pharmaceutical companies, with significant technological breakthroughs in areas such as ADC and GLP-1, leading to increased global competitiveness [10][11]

Core Viewpoint - The approval of Weisheng Pharmaceutical's long-acting growth hormone injection, Longpei, marks a significant advancement in the treatment of pediatric growth hormone deficiency (PGHD) in China, offering a more convenient alternative to daily injections and potentially capturing a substantial share of the high-end market for growth hormone deficiency [1][2][12]. Company Summary - Weisheng Pharmaceutical's Longpei growth hormone injection is the first and only product in China to demonstrate superior efficacy over daily formulations in Phase III clinical trials [1][12]. - The product is based on TransCon technology, which allows for the slow release of a growth hormone structurally identical to the body's own, providing a theoretical safety advantage [6][20]. - The company plans to pursue both original imports and local production partnerships to enhance market access and distribution [9][20]. Industry Summary - The Chinese growth hormone market has grown from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, and is projected to reach 28.6 billion yuan by 2030 [4][14]. - The long-acting growth hormone segment is expected to surpass short-acting products within two years and capture 80% of the market by 2030, indicating a significant shift towards long-acting formulations [4][15]. - The market is currently dominated by Jinsai Pharmaceutical, which is expected to generate revenues of 10.671 billion yuan in 2024, with a net profit of 2.678 billion yuan [15]. Market Dynamics - The market is experiencing a transition from volume expansion to value competition, with a focus on innovative, high-end products [14][15]. - Despite the growth in diagnosis and treatment rates for growth hormone deficiency (GHD) in China, the overall penetration remains significantly lower than in developed countries due to factors such as daily injection compliance challenges, high treatment costs, and limited insurance coverage [2][14]. - Recent price adjustments in long-acting growth hormones are anticipated to improve drug accessibility and create a market split between "insurance-inclusive" and "high-quality" segments [19][20]. Competitive Landscape - The competitive landscape is intensifying with the entry of new players like Teva Biopharma, which is expected to challenge Jinsai Pharmaceutical's dominance in the long-acting segment [5][15]. - The market is characterized by a variety of technological approaches to long-acting growth hormones, including PEGylation and fatty acid side-chain modification, with Weisheng's TransCon technology offering a distinct alternative [20]. - The industry is also witnessing a shift in payment structures and competitive logic, with a growing emphasis on private hospitals and high-end medical institutions for distribution [9][20].

Core Viewpoint - The approval of Rongpei growth hormone injection by the National Medical Products Administration (NMPA) marks a significant advancement in the treatment of pediatric growth hormone deficiency (PGHD) in China, offering a long-acting alternative that has demonstrated superior efficacy compared to daily injections [1][2]. Company Summary - Weisheng Pharmaceutical's Rongpei growth hormone is the first and only long-acting growth hormone in China that has passed phase III clinical trials, showing a higher annualized growth rate compared to daily formulations [1]. - The product is expected to enhance the company's brand presence in the Greater China region, leveraging its clinical validation in the U.S. and successful phase III trial results in the Chinese population [2]. - The company plans to adopt a dual approach for market entry, focusing on both original imports and future local production partnerships [9]. Industry Summary - The Chinese growth hormone market has seen rapid growth, expanding from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, projected to reach 28.6 billion yuan by 2030 [4]. - The market is transitioning from volume expansion to value competition, with long-acting growth hormones expected to dominate the market by 2030, capturing 80% of the market share [4][5]. - The competitive landscape is characterized by a shift towards long-acting formulations, with existing players facing challenges from price competition and the need for differentiation [5][10]. Market Dynamics - The approval of Rongpei growth hormone is anticipated to provide a more convenient treatment option for pediatric patients, potentially increasing market penetration in a segment that has historically lagged behind developed countries [2]. - The market is experiencing a structural change, with a growing emphasis on long-acting products, which are expected to become a significant segment of the market [5][9]. - The pricing landscape is evolving, with recent price adjustments for long-acting growth hormones aimed at improving accessibility and creating a divide between "insurance-inclusive" and "high-end quality" segments [8][9]. Technological Advantages - Rongpei growth hormone utilizes TransCon technology, which allows for a slow release of growth hormone that mimics the natural structure of human growth hormone, providing a theoretical safety advantage over other long-acting products [6][7]. - The product's mechanism of action involves both indirect (80% via IGF-1) and direct pathways (20% directly on growth plates), enhancing its efficacy in promoting height growth [7]. Challenges Ahead - Despite its technological advantages, the commercialization of Rongpei growth hormone faces challenges, particularly regarding pricing and reimbursement issues, as many families are concerned about out-of-pocket costs [8][10]. - The company must navigate hospital access barriers and the evolving reimbursement landscape, which could impact the product's market penetration [8][9].